CGT Catapult has a range of capabilities focused on supporting researchers, start-ups and early-stage companies to rapidly progress their products toward the clinic, help support securing investment and growth of their companies:
The Commercialisation of Research (CoR) programme is dedicated to supporting academic researchers to transition their cell and gene therapy concepts in to investable opportunities and establish start-up companies by securing commercial investment from investors such as venture capitalists.
Using an “in-kind” funding model, the CoR team can provide scientific, technical, commercial, regulatory and medical expertise to mitigate potential risks in therapeutic product development programmes. In addition, the CoR team supports development of business strategies, pitch decks and facilitates introductions to key investors.
We often start with an Investable Opportunity Clinic, where academic groups are provided with translational advice on diverse aspects of cell and gene therapy commercialisation. Dependent upon the capabilities available in partner organisations, the CoR team develops tailor-made support packages to progress collaborators from exciting academic projects to credible commercial opportunities, with the potential to make a meaningful difference to the lives of patients and their families.
ATMP process technologies
Our experienced teams can deliver innovative ways to make your ATMP processes more cost-efficient, scalable, safe, and robust.
Health economics and market analysis
Support to develop robust pricing and reimbursement strategies established at the right stage of your product development.
ATMPs face unique regulatory challenges. We support ATMP developers to address specific risks in their product development and satisfy the relevant national and international legislation and guidance.
Working on a cell or gene therapy innovation challenge?
Contact us today to find out how we can support you.